111, Inc. (NASDAQ:YI) Short Interest Update

111, Inc. (NASDAQ:YI - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 6,600 shares, an increase of 94.1% from the February 28th total of 3,400 shares. Based on an average daily volume of 40,600 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.

111 Price Performance

YI stock traded down $0.94 during trading on Monday, reaching $8.11. 21,699 shares of the company were exchanged, compared to its average volume of 22,146. The company has a market capitalization of $69.36 million, a price-to-earnings ratio of -2.03 and a beta of 0.46. The company has a 50-day moving average of $7.84 and a two-hundred day moving average of $7.45. 111 has a twelve month low of $4.15 and a twelve month high of $14.10.

111 (NASDAQ:YI - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $527.14 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of 111 in a research note on Saturday, March 22nd.

Hedge Funds Weigh In On 111

Large investors have recently bought and sold shares of the company. FIL Ltd bought a new stake in shares of 111 during the fourth quarter worth about $450,000. Napean Trading & Investment Co Singapore PTE Ltd bought a new stake in 111 during the 4th quarter worth approximately $245,000. Finally, JPMorgan Chase & Co. grew its holdings in 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after acquiring an additional 305,339 shares during the last quarter. 21.32% of the stock is currently owned by institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.